Sandu Pharma.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE751D01014
  • NSEID:
  • BSEID: 524703
INR
35.67
-1.13 (-3.07%)
BSENSE

Nov 20

BSE+NSE Vol: 4.42 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 764862,
    "name": "Sandu Pharma.",
    "stock_name": "Sandu Pharma.",
    "full_name": "Sandu Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/sandu-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "35.67",
    "chg": -1.13,
    "chgp": "-3.07%",
    "dir": -1,
    "prev_price": "36.80",
    "mcapval": "35.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524703,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 49,
    "indexname": "",
    "isin": "INE751D01014",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "4.42 k",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/sandu-pharma-764862-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Sandu Pharmaceuticals Downgraded to Strong Sell Amid Flat Financials and Weak Fundamentals",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/sandu-pharmaceuticals-downgraded-to-strong-sell-amid-flat-financials-and-weak-fundamentals-4264762",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/SanduPharmaceut_mojoScore_4264762.png",
        "date": "2026-11-17 08:23:13",
        "description": "Sandu Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 16 Nov 2026, reflecting deteriorating fundamentals and subdued financial performance. Despite an attractive valuation, the company’s weak quality metrics, stagnant financial trends, and poor technical indicators have prompted a reassessment of its investment appeal."
      },
      {
        "title": "Sandu Pharmaceuticals Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/sandu-pharmaceuticals-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-4230641",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/SanduPharmaceut_mojoScore_4230641.png",
        "date": "2026-10-20 08:24:31",
        "description": "Sandu Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 19 Oct 2026, reflecting deteriorating technical indicators and persistently weak financial fundamentals. The micro-cap pharmaceutical company’s stock performance continues to lag behind benchmarks, prompting a reassessment across quality, valuation, financial trend, and technical parameters."
      },
      {
        "title": "Sandu Pharmaceuticals Ltd Rating Upgraded to Sell Amid Technical Improvements",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/sandu-pharmaceuticals-ltd-rating-upgraded-to-sell-amid-technical-improvements-4223757",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/SanduPharmaceut_mojoScore_4223757.png",
        "date": "2026-10-13 08:31:03",
        "description": "Sandu Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators despite persistent fundamental weaknesses. The micro-cap pharmaceutical company’s recent flat financial performance and long-term underperformance contrast with modest improvements in technical trends, prompting a nuanced reassessment of its outlook."
      },
      {
        "title": "Sandu Pharmaceuticals Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/sandu-pharmaceuticals-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-4216978",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/SanduPharmaceut_mojoScore_4216978.png",
        "date": "2026-10-07 08:18:27",
        "description": "Sandu Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating as of 6 October 2026, reflecting deteriorating technical indicators and persistently weak financial fundamentals. Despite a very attractive valuation, the company’s poor long-term growth, flat recent performance, and bearish technical signals have prompted a reassessment of its investment appeal."
      },
      {
        "title": "Sandu Pharmaceuticals Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/sandu-pharmaceuticals-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-4206909",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/SanduPharmaceut_mojoScore_4206909.png",
        "date": "2026-09-28 08:06:55",
        "description": "Sandu Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating as of 25 Sep 2026, reflecting deteriorating technical indicators and persistently weak financial fundamentals. Despite a valuation that appears attractive on paper, the company’s faltering operational performance and bearish market signals have prompted a reassessment of its investment appeal."
      },
      {
        "title": "Sandu Pharmaceuticals Ltd is Rated Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/sandu-pharmaceuticals-ltd-is-rated-sell-4171334",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/SanduPharmaceut_mojoScore_4171334.png",
        "date": "2026-08-27 10:11:02",
        "description": "Sandu Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 August 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook."
      }
    ],
    "total": 28,
    "sid": "764862",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/sandu-pharmaceuticals-764862"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "16-Nov-2026",
      "details": "Newspaper publication in respect of Unaudited Financials for the Q and Half Year ended 30th September 2026",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Dated 14Th November 2026",
      "datetime": "14-Nov-2026",
      "details": "Outcome of the Board Meeting dated 14th November 2026",
      "source": "BSE"
    },
    {
      "caption": "Statement Of Deviation And Variation Of Funds For Q Ended 30Th September 2026",
      "datetime": "14-Nov-2026",
      "details": "statement of deviation and variation of funds for q ended 30th sept 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Sandu Pharmaceuticals Ltd has declared <strong>10%</strong> dividend, ex-date: 04 Sep 26",
          "dt": "2026-09-04",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Newspaper Publication

16-Nov-2026 | Source : BSE

Newspaper publication in respect of Unaudited Financials for the Q and Half Year ended 30th September 2026

Board Meeting Outcome for Outcome Of The Board Meeting Dated 14Th November 2026

14-Nov-2026 | Source : BSE

Outcome of the Board Meeting dated 14th November 2026

Statement Of Deviation And Variation Of Funds For Q Ended 30Th September 2026

14-Nov-2026 | Source : BSE

statement of deviation and variation of funds for q ended 30th sept 2026

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Sandu Pharmaceuticals Ltd has declared 10% dividend, ex-date: 04 Sep 26

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available